secwatch.observer — SEC 8-K summary
======================================

Issuer:     SAFEGUARD SCIENTIFICS INC (SFES)
CIK:        0000086115
Form:       8-K
Filed at:   2022-11-03T23:59:59+00:00
Accession:  0001437749-22-025767
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Safeguard Scientifics Q3 2022 net loss $3.2M vs prior-year net income $18.3M
----------------------------------------------------------------------------

- Received $5.3M initial cash proceeds from Lumesis acquisition, recording a gain of $4.7M.
- Funded $1.6M convertible note in Syapse's $35M growth capital round; capital to expand real-world insights for cancer.
- Trailing 12-month revenues for eight portfolio companies were $139M, up 10.7% YoY.
- Repurchased 84,261 shares in Q3 at avg $4.00; YTD repurchases 453,535 shares for $2.1M.
- Operating costs reduced: G&A expenses $1.4M vs $1.6M in prior-year quarter.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/86115/000143774922025767/0001437749-22-025767-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/86115/000143774922025767/sfe20221102_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-22-025767

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer